Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 3928-3934

  Ichikawa, Wataru ^a   Takahashi, Takehiro ^a   Suto, Kenichi ^a   Sasaki, Yasutsuna ^a   Hirayama, Renzo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; FLUOROURACIL; FOLINIC ACID; GLYCINE; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ALLELE; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DNA EXTRACTION; DNA POLYMORPHISM; DRUG DOSE REDUCTION; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENE EXPRESSION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; TANDEM REPEAT; VOMITING;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OROTATE PHOSPHORIBOSYLTRANSFERASE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 33746102909     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2665     Document Type: Article

References (31)

1. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
2. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-analysis Group In Cancer. J Clin Oncol 1998;16:3537-41.
3. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
4. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-7.
5. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001;19:383-6.
6. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001;19:1779-86.
7. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
8. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005;23:1365-9.
9. Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004;10:5880-8.
10. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994;12:2239-42.
11. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
12. Ichikawa W, Uetake H, Shirota Y, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
13. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5- fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986;46:20-8.
14. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM. A comparison of 5fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991;68:1903-9.
15. Ichikawa W, Uetake H, Shirota Y, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486-92.
16. Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 1979;39:2406-13.
17. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9.
18. Suchi M, Harada N, Tsuboi T, et al. Molecular cloning of human UMP synthase. Adv Exp Med Biol 1989;253A:511-8.
19. Suchi M, Mizuno H, Kawai Y, et al. Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am J Hum Genet 1997;60:525-39.
20. Skibola CF, Forrest MS, Coppede F, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004;104:2155-62.
21. Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res 1979;39:383-90.
22. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003;8:72-8.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
24. Johnston MD. The characteristics required for a Sendai virus preparation to induce high levels of interferon in human lymphoblastoid cells. J Gen Virol 1981;56:175-84.
25. Yoshinare K, Kubota T, Watanabe M, et al. Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 2003;94:633-8.
26. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
27. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001;7:2832-9.
28. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003;9:3021-8.
29. Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998;51:391-400.
30. Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001;92:337-42.
31. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999;58:310-2.